Novel Skin Care Composition for the Treatment of Acne

Abstract

The present invention generally relates to the field of skin care. More specifically, the present invention relates to a cosmetic or therapeutic skin care composition comprising at least one Staphylococcus strain that exerts antimicrobial activity against pathogenic Cutibacterium acnes strains but has no effect on non-pathogenic Cutibacterium acnes strains and promotes the health of at least one skin. The present invention also provides a method for treating or preventing acne, oily skin or dry skin by applying the skin care composition of the present invention to a skin area in need of treatment. The present invention also relates to the use of the skin care composition of the present invention for treating or preventing acne, oily skin or dry skin.

Description

Technical Field

[0001] The present invention generally relates to the field of skin care. More specifically, the present invention exerts antimicrobial activity against pathogenic Cutibacterium acnes strains but does not affect non-pathogenic Cutibacterium acnes strains, and promotes the health of at least one skin, or a cosmetic or therapeutic skin care composition containing the culture supernatant of the above Staphylococcus strain. The present invention also provides a method for treating or preventing acne, oily skin or dry skin by applying the skin care composition of the present invention to a skin area in need of treatment. The present invention also relates to the use of the skin care composition of the present invention for treating or preventing acne, oily skin or dry skin.

[0002] Background of the Invention Acne vulgaris is a widespread and long-term skin condition that affects over 600 million people worldwide. Acne is most commonly seen in teenagers, but people of all ages can be affected. Acne is usually caused by a combination of hyperplasia of the sebaceous glands, excessive sebum production and keratinization disorders. As a result, the hair follicles become clogged with sebum and dead skin cells, resulting in comedones and oily skin (Pschyrembel, Klinisches Woerterbuch, 258. ed., Walter de Gruyter-Verlag, Berlin, 1998). Inflammation can be further caused when bacteria colonize the affected skin area. Acne mainly occurs in skin areas with a large number of sebaceous glands, especially the face, upper chest and back. The occurrence of acne can cause mental distress and mental problems such as low self-esteem and depression.

[0003] Sebaceous skin is a transitional state between healthy skin and acne-prone skin. In sebaceous skin, an excessive amount of sebum is produced from the sebaceous glands of the skin, which subsequently serves as an ideal nutrient for many bacteria and yeasts. These microorganisms further induce sebum production in the sebaceous glands by breaking down sebum into glycerol and fatty acids, and destroy the hair follicle walls of the skin. As a result, inflammation occurs in the skin, and pustules, nodules, and cysts are formed, which often heal with only scars remaining, and the scars have a permanent impact on the optical appearance of the subject's skin (W. Umbach [Ed.], Kosmetik, Entwicklung, Herstellung und Anwendung kosmetischer Mittel, 2. Edition Thieme Verlag, Stuttgart, 1995).

[0004] Currently, the standard treatment for acne usually involves the topical application of antibiotics, including erythromycin, clindamycin, metronidazole, sulfacetamide, doxycycline, or minocycline, to reduce the number of bacteria, particularly C. acnes. However, some of these antibiotics exhibit significant side effects and their use is inconvenient for patients. In addition, antibiotics usually act non-specifically and eradicate all bacteria present on the skin, including those that have a positive effect on skin health. Moreover, the treatment of acne with antibiotics has a high recurrence rate because a small population of pathogenic C. acnes remains after the end of antibiotic treatment and resumes growth.

[0005] Cutibacterium acnes (formerly Propionibacterium acnes), an anaerobic species, is thought to play an important role in the development of acne because these bacteria are usually found in large numbers in patients with moderate or severe inflammatory acne. However, the mechanism of development is not fully understood. In recent years, the putative relationship between acne and the human skin microbiome has been analyzed (Belkaid and Segre, 2014; Oh et al., 2014). Specifically, it has been suggested that acne may be the result of a distortion of the skin microbiome caused by specific strains of C. acnes (Holmes, 2013; Lomholt and Kilian, 2010). Although the skin is colonized by a large number of microorganisms that are harmless or beneficial (Grice and Segre, 2011), changes in the microbiome can potentially cause pathogenic conditions and skin diseases (Bek-Thomsen et al., 2008; Holmes, 2013; Kong et al., 2012; Fitz-Gibbon et al., 2013). This distortion can be caused by a specific subset of C. acnes strains (Lomholt and Kilian, 2010). On the other hand, another subset of C. acnes strains has also been reported to be involved in the stabilization of healthy skin conditions.

[0006] Therefore, there is a need for new methods of treating or preventing acne that specifically eradicate the strains that induce or exacerbate acne while maintaining the strains that have a positive effect on skin health. Such methods should be essentially free of side effects and provide long-lasting effects.

[0007] Summary of the Invention In a first aspect, the present invention relates to a skin care composition for topical administration to the skin, the skin care composition comprising one or more Staphylococcus strains that exhibit antimicrobial activity specific for pathogenic C. acnes strains, or a culture supernatant obtained from such Staphylococcus strains.

[0008] In the context of the present invention, a Staphylococcus strain is considered to exhibit activity against a C. acnes strain if the strain shows activity in the following lawn assay. A culture of the Staphylococcus strain is prepared and incubated in CASO broth at 37°C overnight until an OD 600 reaches 8.0. Subsequently, 15 μl of the overnight culture is pipetted onto a lawn plate of each C. acnes strain containing at least 1×10 8 CFU / plate. The Staphylococcus strain has activity against the C. acnes strain if an inhibition zone appears around the application site after 96 hours of anaerobic incubation of the plate at 37°C.

[0009] Preferably, the one or more Staphylococcus strains that exhibit antimicrobial activity are (a) S. hominis HAA254 deposited with DSMZ under accession number DSM 34166, (b) S. hominis HAA272 deposited with DSMZ under accession number DSM 34167, (c) S. capitis HAB56 deposited with DSMZ under accession number DSM 34177, (d) S. capitis HAB177 deposited with DSMZ under accession number DSM 34178, (e) S. capitis HAB198 deposited with DSMZ under accession number DSM 34179, (f) S. capitis HAB276 deposited with DSMZ under accession number DSM 34197, (g) S. hominis HAC286 deposited with DSMZ under accession number DSM 34168, (h) S. capitis HAC349 deposited with DSMZ under accession number DSM 34198, (i) S. capitis HAC470 deposited with DSMZ under accession number DSM 34199, (j) S. capitis HAC507 deposited with DSMZ under accession number DSM 34200, (k) S. epidermidis HAC588 deposited with DSMZ under accession number DSM 34158, (l) S. epidermidis HAF242 deposited with DSMZ under accession number DSM 34159, (m) S. capitis HAF401 deposited with DSMZ under accession number DSM 34153, (n) S. epidermidis HAF424 deposited with DSMZ under accession number DSM 34160, (o) S. epidermidis HAC26 deposited with DSMZ under accession number DSM 34117, (p) S. warneri HAA333 deposited with DSMZ under accession number DSM 34118 selected from the group consisting of.

[0010] Any single or combination of the above strains, or the culture supernatant obtained from any of these strains, can be used in the composition of the present invention. In one embodiment, the Staphylococcus strain is present in the composition in freeze-dried or spray-dried form. The Staphylococcus strain is preferably 104 ~10 11 CFU / ml, preferably 10 7 ~10 10 present in the composition in an amount of CFU / ml. The Staphylococcus strain may be present in the composition in an amount of at least 0.5% (w / v) of the skin care composition.

[0011] In a particularly preferred embodiment, the skin care composition of the present invention comprises two or more of the above strains. When two or more of the Staphylococcus strains HAA254, HAA272, HAB56, HAB177, HAB198, HAB276, HAC286, HAC349, HAC470, HAC507, HAC588, HAF242, HAF401, HAF424, HAC26 and HAA333 are used in combination in the same skin care composition, it is particularly preferred that these strains are present in the composition at approximately equal concentrations, such as 1:1 or 1:1:1.

[0012] When the culture supernatant is used, the supernatant is preferably sterile filtered before being added to the skin care composition.

[0013] In one embodiment, the skin care composition further comprises one or more additives, and the one or more additives preferably include emollients, fillers, thickeners, solubilizers, antioxidants, preservatives, pH adjusters, binders, buffers, colorants, moisturizers, keratolytic agents, preservatives, plant extracts, essential oils or fragrances.

[0014] The skin care composition is preferably formulated as a gel, cream, ointment or lotion.

[0015] In a second aspect, the present invention relates to a skin care composition for use in a method of treating acne, oily skin and / or dry skin in a subject, for use in a method of reducing the number of pathogenic C. acnes cells on the skin of a subject, and / or for use in a method of treating an infection of the skin of a subject by pathogenic C. acnes cells.

[0016] In a third aspect, the present invention relates to S. hominis HAA254 deposited with the DSMZ under accession number DSM 34166, S. hominis HAA272 deposited with the DSMZ under accession number DSM 34167, S. capitis HAB56 deposited with the DSMZ under accession number DSM 34177, S. capitis HAB177 deposited with the DSMZ under accession number DSM 34178, S. capitis HAB198 deposited with the DSMZ under accession number DSM 34179, S. capitis HAB276 deposited with the DSMZ under accession number DSM 34197, S. hominis HAC286 deposited with the DSMZ under accession number DSM 34168, S. capitis HAC349 deposited with the DSMZ under accession number DSM 34198, S. capitis HAC470 deposited with the DSMZ under accession number DSM 34199, S. capitis HAC507 deposited with the DSMZ under accession number DSM 34200, S. epidermidis HAC588 deposited with the DSMZ under accession number DSM 34158, S. epidermidis HAF242 deposited with the DSMZ under accession number DSM 34159, S. capitis HAF401 deposited with the DSMZ under accession number DSM 34153, S. epidermidis HAF424 deposited with the DSMZ under accession number DSM 34160, S. epidermidis HAC26 deposited with the DSMZ under accession number DSM 34117, S. warneri HAA333 deposited with the DSMZ under accession number DSM 34118, or a culture supernatant obtained from any of these strains.

Brief Description of the Drawings

[0017]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

[0018] Detailed description The present invention provides a novel Staphylococcus strain isolated from the natural environment that exhibits significant activity against pathogenic C. acnes strains, particularly C. acnes strains that occur in the skin of individuals suffering from acne. When applied to the skin, these strains secrete antibacterial compounds into the surrounding medium and selectively kill pathogenic C. acnes cells, effectively reducing the number of pathogenic C. acnes cells on the skin. The present invention also relates to the culture supernatant of any of these strains.

[0019] C. acnes is a polyphyletic species that can be classified into different subspecies and phylotypes, namely IA1, IA2, IB, IC, II, and III (Lomholt et al. 2010, McDowell et al. 2013). To enable the characterization of mixed populations of C. acnes, a single-locus sequence typing (SLST) scheme was developed that allows for subdivision into 10 classes (A - L) (Scholz et al. 2014). SLST classes A - E correspond to phylotype IA1 strains, and SLST classes F, G, H, K, and L correspond to phylotypes IA2, IC, IB, II, and III, respectively (Scholz et al. 2014). Recent studies have shown that several phylotypes / SLST classes are increased in individuals with the skin disorder acne vulgaris, while other phylotypes / SLST classes have been identified as markers of healthy skin. Acne-associated phylotypes include SLST classes A and C (both phylotype IA1) and F (IA2), and a more diverse population colonizes healthy skin, with a higher prevalence of strains belonging to SLST classes H (IB) and K (II) (Dagnelie et al. 2018, Lomholt et al. 2017, McDowell et al. 2012, McDowell et al. 2011, Nakase et al. 2017, Nakase et al. 2020).

[0020] The Staphylococcus strains identified in the process of the present invention have been found to have significantly higher activity against C. acnes strains associated with acne-affected skin, particularly strains of SLST classes A, C, and F. At the same time, these strains show reduced activity or no activity against C. acnes strains associated with healthy skin, particularly strains of SLST classes H and K.

[0021] In a preferred embodiment, the present invention provides a Staphylococcus strain having activity against one or more C. acnes strains of SLST class A. In another embodiment, the present invention provides a Staphylococcus strain having activity against one or more C. acnes strains of SLST classes A and C. In yet another embodiment, the present invention provides a Staphylococcus strain having activity against one or more C. acnes strains of SLST classes A, C, and F. In a preferred embodiment, the present invention provides a Staphylococcus strain having activity against one or more C. acnes strains of SLST class A but not against C. acnes strains of SLST class H. In another embodiment, the present invention provides a Staphylococcus strain having activity against one or more C. acnes strains of SLST classes A and C but not against C. acnes strains of SLST class H. In yet another embodiment, the present invention provides a Staphylococcus strain having activity against one or more C. acnes strains of SLST class A but not against C. acnes strains of SLST classes H and K. In yet another embodiment, the present invention provides a Staphylococcus strain having activity against one or more C. acnes strains of SLST classes A and C but not against C. acnes strains of SLST classes H and K.

[0022] Accordingly, the present invention also provides a skin care composition for topical administration to the skin, comprising one or more Staphylococcus strains that exhibit specific antimicrobial activity against pathogenic C. acnes strains. The present invention also relates to the culture supernatant of any of these strains. The one or more Staphylococcus strains are preferably (a) S. hominis HAA254 deposited with DSMZ under accession number DSM 34166, (b) S. hominis HAA272 deposited with DSMZ under accession number DSM 34167, (c) S. capitis HAB56 deposited with DSMZ under accession number DSM 34177, (d) S. capitis HAB177 deposited with DSMZ under accession number DSM 34178, (e) S. capitis HAB198 deposited with DSMZ under accession number DSM 34179, (f) S. capitis HAB276 deposited with DSMZ under accession number DSM 34197, (g) S. hominis HAC286 deposited with DSMZ under accession number DSM 34168, (h) S. capitis HAC349 deposited with DSMZ under accession number DSM 34198, (i) S. capitis HAC470 deposited with DSMZ under accession number DSM 34199, (j) S. capitis HAC507 deposited with DSMZ under accession number DSM 34200, (k) S. epidermidis HAC588 deposited with DSMZ under accession number DSM 34158, (l)S. epidermidis HAF242, deposited with DSMZ under accession number DSM 34159, (m)S. capitis HAF401, deposited with DSMZ under accession number DSM 34153, (n)S. epidermidis HAF424, deposited with DSMZ under accession number DSM 34160, (o)S. epidermidis HAC26, deposited with DSMZ under accession number DSM 34117, (p)S. warneri HAA333 deposited with DSMZ under accession number DSM 34118 selected from the group consisting of.

[0023] These strains or culture supernatants obtained from these strains can be used as active ingredients in skin care compositions of cosmetics and pharmaceuticals that are topically applied to the skin having an excessive number of one or more pathogenic C. acnes strains by their ability to control and reduce the abundance of pathogenic C. acnes strains on human skin. Without wishing to be bound by theory, the activity of the strains of the present invention is thought to be based on the production and secretion of antibacterial compounds that are active against pathogenic S. aureus strains. Since these antibacterial compounds are secreted into the surrounding medium, it is also possible to use the culture supernatant obtained from the above strains. As used in the present invention, the culture supernatant is a fraction of the cell culture medium in which compounds secreted from the cultured cells are accumulated and which is used for culturing the cells.

[0024] Preferably, one or more Staphylococcus strains are present in the skin care composition of the present invention in a lyophilized or spray-dried form. This means that viable bacteria have been subjected to a drying process that maintains their viability while minimizing their metabolic processes. In the lyophilized or spray-dried form, the bacteria can be stored for several months or even years. When applied to the skin such as human skin, the metabolism of the bacteria is reactivated and growth resumes. As this bacterium grows on the skin surface and replaces pathogenic bacterial strains, a diverse and healthy balanced skin microbiome is restored.

[0025] In one embodiment, one or more Staphylococcus strains are present in spray-dried form. The principle of spray drying is based on the dispersion of a solution into fine droplets introduced into a hot air stream. As the solvent evaporates from the substrate droplets, clusters of the dried product remain. Standard spray drying apparatuses such as the Mini Spray Dryer B-290 of Buechi Labortechnik GmbH (Essen, Germany) or the Mobile Minor™ Spray Dryer of GEA (Berlin, Germany) can be used. In another embodiment, one or more Staphylococcus strains are present in freeze-dried or lyophilized form. Freeze-drying or lyophilization is a process that involves freezing the product, reducing the pressure, and applying heat to sublimate the frozen water in the material. Various methods can be applied to freeze the product. For example, freezing can be achieved using a standard freezer or a chilled bath. By cooling the product below its triple point, sublimation is ensured upon heating. Freezing is carried out rapidly to prevent the formation of large crystals that could potentially damage the structure of the product being dried. When the frozen water sublimates, approximately 95% of the water in the product is removed. Most materials can be dried to a residual moisture content of 1 - 5%. Standard freeze-drying apparatuses such as the Lyovac™ apparatus of GEA (Berlin, Germany), the Gamma 2-20 Freeze dryer LCM-1 of Christ (Osterode am Harz, Germany), or the Christ Martin™ Alpha 1-2 Lyophilisator of Fisher Scientific GmbH (Schwerte, Germany) can be used.

[0026] The Staphylococcus strain is 1.0×10 4 ~1.0×10 11 colony-forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9It is preferably present in the composition in an amount of CFU / ml. For example, Staphylococcus strains HAA254, HAA272, HAB56, HAB177, HAB198, HAB276, HAC286, HAC349, HAC470, HAC507, HAC588, HAF242, HAF401, HAF424, HAC26 or HAA333 are at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml may be present. When the Staphylococcus strain is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml is particularly preferably present.

[0027] In one embodiment, S. hominis strain HAA254 is 1.0×10 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9present in the composition in an amount of CFU / ml. For example, S. hominis strain HAA254 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml. S. hominis strain HAA254 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml. It is particularly preferred that it is present in an amount of.

[0028] In another embodiment, S. hominis strain HAA272 is 1.0×10 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml present in the composition. For example, S. hominis strain HAA272 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml, or may be present in an amount of at least 1.0×10 10 CFU / ml. S. hominis strain HAA272 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml in amount is particularly preferred.

[0029] In yet another embodiment, S. capitis strain HAB56 is 1.0×10 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml in the composition. For example, S. capitis strain HAB56 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10It may be present in an amount of CFU / ml. S. capitis strain HAB56 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml is particularly preferably present.

[0030] In yet another embodiment, S. capitis strain HAB177 is 1.0×10 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml is present in the composition. For example, S. capitis strain HAB177 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml may be present. S. capitis strain HAB177 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 It is particularly preferred to be present in an amount of CFU / ml.

[0031] In yet another embodiment, the S. capitis strain HAB198 is 1.0×10 per 1 ml 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml is present in the composition. For example, the S. capitis strain HAB198 is at least 1.0×10 in the skin care composition 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml can be present. The S. capitis strain HAB198 is at least 1.0×10 in the skin care composition 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10It is particularly preferred to be present in an amount of CFU / ml.

[0032] In yet another embodiment, S. capitis strain HAB276 is 1.0×10 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 present in the composition in an amount of CFU / ml. For example, S. capitis strain HAB276 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml. S. capitis strain HAB276 can be present in the skin care composition in an amount of at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 It is particularly preferred to be present in an amount of CFU / ml.

[0033] In yet another embodiment, S. hominis strain HAC286 is 1.0×10 4 ~1.0×10 11Colony - forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml is present in the composition. For example, S. hominis strain HAC286 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml can be present. S. hominis strain HAC286 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml is particularly preferably present.

[0034] In yet another embodiment, S. capitis strain HAC349 is 1.0×10 4 ~1.0×10 11 colony - forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×109 present in the composition in an amount of CFU / ml. For example, S. capitis strain HAC349 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml may be present. S. capitis strain HAC349 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml is particularly preferably present in the amount.

[0035] In yet another embodiment, S. capitis strain HAC470 is 1.0×10 4 to 1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 to 1.0×10 10 CFU / ml, even more preferably 1.0×10 7 to 1.0×10 10 CFU / ml or 1.0×10 8 to 1.0×10 9 CFU / ml is present in the composition in an amount. For example, S. capitis strain HAC470 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml and may be present in an amount of. S. capitis strain HAC470 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml and is particularly preferably present in an amount of.

[0036] In yet another embodiment, S. capitis strain HAC507 is 1.0×10 per 1 ml 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml and is present in the composition in an amount of. For example, S. capitis strain HAC507 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10It may be present in an amount of CFU / ml. S. capitis strain HAC507 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml in the amount is particularly preferred.

[0037] In yet another embodiment, S. epidermidis strain HAC588 is 1.0×10 per 1 ml 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml in the composition. For example, S. epidermidis strain HAC588 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml in the amount may be present. S. epidermidis strain HAC588 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 It is particularly preferred to be present in an amount of CFU / ml.

[0038] In yet another embodiment, S. epidermidis strain HAF242 is 1.0×10 per 1 ml 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml is present in the composition. For example, S. epidermidis strain HAF242 is at least 1.0×10 of the skin care composition 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml can be present. S. epidermidis strain HAF242 is at least 1.0×10 of the skin care composition 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10CFU / ml or 9.0×10 10 It is particularly preferred to be present in an amount of CFU / ml.

[0039] In yet another embodiment, S. capitis strain HAF401 is 1.0×10 per 1 ml 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 present in the composition in an amount of CFU / ml. For example, S. capitis strain HAF401 is at least 1.0×10 of the skin care composition 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml can be present in an amount. S. capitis strain HAF401 is at least 1.0×10 of the skin care composition 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 It is particularly preferred to be present in an amount of CFU / ml.

[0040] In yet another embodiment, S. epidermidis strain HAF424 is 1.0×10 per 1 ml4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 present in the composition in an amount of ~1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml may be present. S. epidermidis strain HAF424 is present in the skin care composition in an amount of at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml is particularly preferably present.

[0041] In yet another embodiment, S. epidermidis strain HAC26 is 1.0×10 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×1010 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml is present in the composition. For example, S. epidermidis strain HAC26 is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml may be present. S. epidermidis strain HAC26 is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml is particularly preferably present.

[0042] In yet another embodiment, S. warneri strain HAA333 is 1.0×10 4 ~1.0×10 11 colony forming units (CFU), more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml is present in the composition. For example, S. warneri strain HAA333 is at least 1.0×10 5CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml and may be present in an amount of. S. warneri strain HAA333 is at least 1.0×10 of the skin care composition 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml and is particularly preferably present in an amount of.

[0043] In other words, the skin care composition of the present invention contains a Staphylococcus strain in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. For example, the skin care composition of the present invention contains at least 0.5% (w / v) of Staphylococcus strain HAA254, strain HAA272, strain HAB56, strain HAB177, strain HAB198, strain HAB276, strain HAC286, strain HAC349, strain HAC470, strain HAC507, strain HAC588, strain HAF242, strain HAF401, strain HAF424, strain HAC26 or strain HAA333. More preferably, the skin care composition of the present invention contains at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) of S. epidermidis strain based on the total volume of the skin care composition.

[0044] In one embodiment, the skin care composition of the present invention contains S. hominis strain HAA254 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention contains S. hominis strain HAA254 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0045] In another embodiment, the skin care composition of the present invention contains S. hominis strain HAA272 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention contains S. hominis strain HAA272 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0046] In yet another embodiment, the skin care composition of the present invention contains S. capitis strain HAB56 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention contains S. capitis strain HAB56 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0047] In yet another embodiment, the skin care composition of the present invention comprises S. capitis strain HAB177 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. capitis strain HAB177 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0048] In yet another embodiment, the skin care composition of the present invention comprises S. capitis strain HAB198 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. capitis strain HAB198 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0049] In yet another embodiment, the skin care composition of the present invention comprises S. epidermidis strain HAB276 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. epidermidis strain HAB276 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0050] In yet another embodiment, the skin care composition of the present invention comprises S. hominis strain HAC286 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. hominis strain HAC286 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0051] In yet another embodiment, the skin care composition of the present invention comprises S. capitis strain HAC349 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. capitis strain HAC349 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0052] In yet another embodiment, the skin care composition of the present invention comprises S. capitis strain HAC470 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. capitis strain HAC470 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0053] In yet another embodiment, the skin care composition of the present invention comprises S. capitis strain HAC507 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. capitis strain HAC507 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0054] In yet another embodiment, the skin care composition of the present invention comprises S. epidermidis strain HAC588 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. epidermidis strain HAC588 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0055] In yet another embodiment, the skin care composition of the present invention comprises S. epidermidis strain HAF242 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. epidermidis strain HAF242 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0056] In yet another embodiment, the skin care composition of the present invention comprises S. capitis strain HAF401 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. capitis strain HAF401 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0057] In yet another embodiment, the skin care composition of the present invention comprises S. epidermidis strain HAF424 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. epidermidis strain HAF424 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0058] In yet another embodiment, the skin care composition of the present invention comprises S. epidermidis strain HAC26 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. epidermidis strain HAC26 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0059] In yet another embodiment, the skin care composition of the present invention comprises S. warneri strain HAA333 in an amount of at least 0.5% (w / v) based on the total volume of the skin care composition. More preferably, the skin care composition of the present invention comprises S. warneri strain HAA333 in an amount of at least 0.75% (w / v), at least 1.0% (w / v), at least 1.25% (w / v), at least 1.5% (w / v), at least 1.75% (w / v), at least 2.0% (w / v), at least 2.25% (w / v) or at least 2.5% (w / v) based on the total volume of the skin care composition.

[0060] When two or more Staphylococcus strains are used in combination in the same skin care composition, each strain is preferably 1.0×10 4 ~1.0×10 11 CFU / ml, more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml and is present in the composition in an amount of. For example, each of the strains is at least 1.0×10 5 CFU / ml, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml and may be present in an amount of. Each of the strains is at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml, and it is particularly preferred to be present in such an amount.

[0061] In some embodiments, the total amount of freeze-dried or spray-dried bacteria in the composition is 1.0×10 4 ~1.0×10 11 CFU / ml, more preferably 1.0×10 5 ~1.0×10 10 CFU / ml, even more preferably 1.0×10 7 ~1.0×10 10 CFU / ml or 1.0×10 8 ~1.0×10 9 CFU / ml. For example, the bacteria, in total, are at least 1.0×10 5 CFU / ml in the skin care composition, preferably at least 1.0×10 6 CFU / ml, more preferably at least 1.0×10 7 CFU / ml, for example at least 1.0×10 8 CFU / ml, at least 1.0×10 9 CFU / ml or at least 1.0×10 10 CFU / ml, and can be present in the composition in such an amount. The bacteria, in total, are at least 1.0×10 10 CFU / ml, 2.0×10 10 CFU / ml, 3.0×10 10 CFU / ml, 4.0×10 10 CFU / ml, 5.0×10 10 CFU / ml, 6.0×10 10 CFU / ml, 7.0×10 10 CFU / ml, 8.0×10 10 CFU / ml or 9.0×10 10 CFU / ml, and it is particularly preferred to be present in the composition in such an amount. A person skilled in the art can easily determine the amount of bacteria in the freeze-dried or spray-dried composition.

[0062] When two or more Staphylococcus strains HAA254, HAA272, HAB56, HAB177, HAB198, HAB276, HAC286, HAC349, HAC470, HAC507, HAC588, HAF242, HAF401, HAF424, HAC26 and HAA333 are used in combination in the same skin care composition, it is particularly preferred that these strains be present in the composition at approximately equal concentrations, for example 1:1 or 1:1:1.

[0063] In one embodiment, the culture supernatant of one or more cultures of the strains of the present invention is added to the skin care composition of the present invention. Preferably, the culture supernatant is sterile filtered before being added to the skin care composition. For example, the culture supernatant can be sterile filtered by centrifuging an overnight culture at 8000 g for 10 minutes and subsequently filtering the supernatant through a filter with a pore size of 0.2 μm.

[0064] The skin care composition of the present invention can be formulated as a liquid, ointment, cream, scrub, lotion, paste, gel, hydrogel, foam or powder. However, it is preferably formulated as a gel, cream, ointment or lotion. It can be filled into a pump dispenser capable of dispensing a liquid onto the skin area to be treated by formulating the skin care composition. The skin care composition of the present invention can also be incorporated into a patch applied to the skin.

[0065] The composition of the present invention may optionally contain one or more additives commonly used in cosmetic or pharmaceutical skin care products. Such additives are described in detail, for example, in the International Cosmetic Ingredient Dictionary and Handbook, 16th ed. (2016). For example, the one or more additives may include emollients, keratolytic agents, humectants, pH adjusters, thickeners, solubilizers, antioxidants, preservatives, fillers, binders, buffers, colorants, essential oils, pigments, sunscreens, antiseptics, chelating agents, vitamins, panthenol, coenzyme Q10, hyaluronic acid or any combination thereof.

[0066] For example, the skin care composition of the present invention may contain a skin softening agent. When used in the present invention, the skin softening agent is a compound that moisturizes and / or softens the skin. The skin softening agent usually penetrates deep into the skin to reduce skin roughness, cracking and / or inflammation. Examples of skin softening agents suitable for the skin care composition of the present invention include, but are not limited to, olive oil, palm oil, soybean oil, sesame oil, rapeseed oil, evening primrose oil, sunflower seed oil, avocado oil, olive oil, coconut oil, castor oil, safflower oil, myristyl lactate, isopropyl myristate, polyethylene glycol, isopropyl palmitate, isopropyl stearate, isobutyl palmitate, isocetyl stearate or cetyl alcohol. Preferably, the skin softening agent is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 10% (w / w), preferably 0.1 to 10.0% (w / w), more preferably 1.0 to 10.0% (w / w) based on the total weight of the composition. In another embodiment, the skin softening agent is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 5.0% (w / w), preferably 0.1 to 5.0% (w / w), more preferably 1.0 to 5.0% (w / w) based on the total weight of the composition. The skin care composition of the present invention may contain two or more skin softening agents. In this case, the above amounts preferably refer to the total amount of skin softening agents in the composition.

[0067] The skin care composition of the present invention may contain a keratolytic compound. The keratolytic compound is a solid that provides a granular texture to the composition. When rubbed on the skin, these compounds remove old skin cells and promote skin regeneration. Examples of keratolytic compounds useful in the composition of the present invention include, but are not limited to, urea, α-hydroxy acids and β-hydroxy acids, and their esters, anhydrides and salts. Suitable hydroxy acids include, for example, urea, glycolic acid, lactic acid, malic acid, mandelic acid, tartaric acid, citric acid, 2-hydroxyalkanoic acid, salicylic acid and their derivatives. The use of urea is particularly preferred because urea has an additional water-binding effect and enhances the absorption of other cosmetic ingredients. Preferably, the keratolytic compound is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 10% (w / w), preferably 0.1 to 10.0% (w / w), more preferably 1.0 to 10.0% (w / w) based on the total weight of the composition. In another embodiment, the keratolytic compound is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 5.0% (w / w), preferably 0.1 to 5.0% (w / w), more preferably 1.0 to 5.0% (w / w) based on the total weight of the composition. The skin care composition of the present invention may contain two or more keratolytic compounds. In this case, the above amounts preferably refer to the total amount of keratolytic compounds in the composition.

[0068] The skin care composition of the present invention may contain a humectant for improving the water content of the skin. Suitable humectants used in the composition of the present invention include glycerin, polyethylene glycol ethers of glycerin, amino acids such as proline and arginine, sugars and sugar alcohols such as glucose, mannose, trehalose and polyglycerol sorbitol, 1,3-butylene glycol, propylene glycol, diglycerol, glycerol monopropoxylate, glycogen, sodium hyaluronate, sodium polyaspartate, sodium polyglutamate, sorbes 20, sorbes 6, and hydrolyzed hydrogenated starch, but are not limited thereto. Preferably, the humectant is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 10% (w / w), preferably 0.1 to 10.0% (w / w), more preferably 1.0 to 10.0% (w / w) based on the total weight of the composition. In another embodiment, the humectant is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 5.0% (w / w), preferably 0.1 to 5.0% (w / w), more preferably 1.0 to 5.0% (w / w) based on the total weight of the composition. The skin care composition of the present invention may contain two or more humectants. In this case, the above amounts preferably refer to the total amount of humectants in the composition.

[0069] In a preferred embodiment, the skin care composition of the present invention contains a compound that acts as a pH adjuster. Since the composition of the present invention is used for human skin, it usually has a slightly acidic pH so as to be compatible with the acidic environment of the skin. The composition can have a pH in the range of about 2.5 to about 6.5, preferably about 4.0 to about 6.0, more preferably about 5.0 to about 6.0 or about 5.5 to about 6.0. The acidic pH can be achieved by adding an acid, such as a carboxylic acid like an α-hydroxy acid, to the skin care composition of the present invention. The nature of the acid that can be used in the composition of the present invention is not particularly limited. Suitable acids include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, and the like. In a particularly preferred embodiment, the composition contains lactic acid as a pH adjuster. For application to human skin, lactic acid is also secreted by the skin microbiota and is particularly useful for forming a protective acidic environment on the human skin surface. Preferably, the pH adjuster is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 10% (w / w), preferably 0.1 to 10.0% (w / w), more preferably 1.0 to 10.0% (w / w) based on the total weight of the composition. In another embodiment, the pH adjuster is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 5.0% (w / w), preferably 0.1 to 5.0% (w / w), more preferably 1.0 to 5.0% (w / w) based on the total weight of the composition. The skin care composition of the present invention may contain two or more pH adjusters. In this case, the above amounts preferably refer to the total amount of the pH adjusters in the composition.

[0070] In a preferred embodiment, the skin care composition of the present invention contains a thickening agent. A thickening agent is a compound that increases the viscosity of a cosmetic or pharmaceutical formulation. A thickening agent is often a polymer that makes the composition more viscous by absorbing water and swelling. Examples of thickening agents suitable for the skin care composition of the present invention include, but are not limited to, bean gum, xanthan gum, gelatin, carnauba wax, stearic acid, C. crispus extract, hydroxypropyl phosphate starch, and mixtures thereof. Preferably, the thickening agent is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 10% (w / w), preferably 0.1 to 10.0% (w / w), more preferably 1.0 to 10.0% (w / w) based on the total weight of the composition. In another embodiment, the thickening agent is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 5.0% (w / w), preferably 0.1 to 5.0% (w / w), more preferably 1.0 to 5.0% (w / w) based on the total weight of the composition. The skin care composition of the present invention may contain two or more thickening agents. In this case, the above amounts preferably refer to the total amount of thickening agents in the composition.

[0071] In a preferred embodiment, the skin care composition of the present invention contains a solubilizing agent. When used in the present invention, the solubilizing agent is a compound that aids in the solubilization of hydrophobic substances in aqueous and alcoholic formulations. For example, the solubilizing agent can enable the solubilization of essential oils and other hydrophobic substances, such as vitamins, into an aqueous skin care composition. Suitable solubilizing agents for the skin care composition of the present invention include pentaerythrityl tetraisostearate, polyglyceryl-4 caprate, polyglyceryl-3 cocoate, polyglyceryl-10 caprylate, and various poloxamers such as poloxamer 188, 234, 235, 238, and 338, but are not limited thereto. Preferably, the solubilizing agent is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 10% (w / w), preferably 0.1 to 10.0% (w / w), more preferably 1.0 to 10.0% (w / w) based on the total weight of the composition. In another embodiment, the solubilizing agent is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 5.0% (w / w), preferably 0.1 to 5.0% (w / w), more preferably 1.0 to 5.0% (w / w) based on the total weight of the composition. The skin care composition of the present invention may contain two or more solubilizing agents. In this case, the above amounts preferably refer to the total amount of solubilizing agents in the composition.

[0072] In a preferred embodiment, the skin care composition of the present invention contains an antioxidant. These compounds are usually added to cosmetic or pharmaceutical formulations to prevent oxidation reactions catalyzed by oxygen radicals that would otherwise cause degradation of components in the composition such as proteins, sugars and lipids. Antioxidants commonly used in cosmetics include butylated hydroxytoluene, butyl hydroxyanisole, tocopherol, tocopherol acetate, and substances such as plant-derived polyphenols, flavonoids, flavanols, stilbenes and terpenes. Preferably, the antioxidant is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 10% (w / w), preferably 0.1 to 10.0% (w / w), more preferably 1.0 to 10.0% (w / w) based on the total weight of the composition. In another embodiment, the antioxidant is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 5.0% (w / w), preferably 0.1 to 5.0% (w / w), more preferably 1.0 to 5.0% (w / w) based on the total weight of the composition. The skin care composition of the present invention may contain two or more antioxidants. In this case, the above amounts preferably refer to the total amount of antioxidants in the composition.

[0073] In a preferred embodiment, the skin care composition of the present invention contains a preservative. When used in the present invention, a preservative is a compound added to a cosmetic or pharmaceutical formulation to prevent microbial spoilage of the formulation by inhibiting the growth of unintended bacteria and yeasts. Preservatives commonly used in cosmetic formulations include, in particular, benzyl alcohol, ethanol, phenoxyethanol, caprylyl glycol, salicylic acid, and sorbic acid. Preferably, the preservative is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 10% (w / w), preferably 0.1 to 10.0% (w / w), more preferably 1.0 to 10.0% (w / w) based on the total weight of the composition. In another embodiment, the preservative is present in the skin care composition of the present invention in an amount of 0.05% (w / w) to 5.0% (w / w), preferably 0.1 to 5.0% (w / w), more preferably 1.0 to 5.0% (w / w) based on the total weight of the composition. The skin care composition of the present invention may contain two or more preservatives. In this case, the above amounts preferably refer to the total amount of preservatives in the composition.

[0074] When used in the present invention, unless otherwise specified, all percentages are by weight of the skin care composition. All ratios are by weight unless otherwise specified.

[0075] The novel strains of the present invention, as well as culture supernatants obtained from any of these strains, and skin care compositions containing one or more of the described strains or their culture supernatants are useful for modulating the skin microbiome, particularly for reducing the number of pathogenic C. acnes cells on the skin of a subject. Accordingly, the strains, culture supernatants, and skin care compositions of the present invention are particularly useful for the treatment of skin infections and skin diseases caused by pathogenic C. acnes, such as seborrheic skin and / or acne, which are characterized by an excess of pathogenic C. acnes cells on the skin.

[0076] Therefore, in a preferred embodiment, the present invention relates to a method for reducing the number of pathogenic C. acnes cells on the skin of a subject, which uses one of the above-mentioned Staphylococcus strains or a culture supernatant obtained from such a strain, or a combination of two or more of these strains or their culture supernatants, or the above-mentioned skin care composition containing one or more of these strains or their culture supernatants. The present invention also relates to the use of one of the above-mentioned Staphylococcus strains or a culture supernatant obtained from such a strain, or a combination of two or more of these strains or their culture supernatants, or the above-mentioned skin care composition containing one or more of these strains or their culture supernatants for reducing the number of pathogenic C. acnes cells on the skin of a subject. The present invention also relates to a method for reducing the number of pathogenic C. acnes cells on the skin of a subject, which comprises administering to the skin of a subject in need thereof the above-mentioned skin care composition containing one of the above-mentioned Staphylococcus strains or its culture supernatant, or a combination of these strains or their culture supernatants, or one or more of these strains or their culture supernatants. It is particularly preferred that the subject to be treated is a human.

[0077] In another preferred embodiment, the present invention relates to one of the above-mentioned Staphylococcus strains, a culture supernatant obtained from such a strain, or a combination of these strains or their culture supernatants, or the above-mentioned skin care composition containing one or more of these strains or their culture supernatants, which is used in a method for treating skin infections caused by pathogenic C. acnes in a subject. The present invention also relates to the use of one of the above-mentioned Staphylococcus strains, a culture supernatant obtained from such a strain, or a combination of these strains or their culture supernatants, or the above-mentioned skin care composition containing one or more of these strains or their culture supernatants, for treating skin infections caused by pathogenic C. acnes in a subject. The present invention also relates to a method for treating skin infections caused by pathogenic C. acnes in a subject, which comprises administering to the skin of a subject in need thereof one of the above-mentioned Staphylococcus strains, a culture supernatant obtained from such a strain, or a combination of these strains or their culture supernatants, or the above-mentioned skin care composition containing one or more of these strains or their culture supernatants. It is particularly preferred that the subject to be treated is a human.

[0078] In yet another preferred embodiment, the present invention relates to one of the above-mentioned Staphylococcus strains, a culture supernatant obtained from such a strain, or a combination of these strains or their culture supernatants, or the above-mentioned skin care composition comprising one or more of these strains or their culture supernatants, which is used in a method for treating seborrheic skin, acne and / or dry skin in a subject. The present invention also relates to the use of one of the above-mentioned Staphylococcus strains, a culture supernatant obtained from such a strain, or a combination of these strains or their culture supernatants, or the above-mentioned skin care composition comprising one or more of these strains or their culture supernatants, for treating seborrheic skin, acne and / or dry skin in a subject. The present invention also relates to a method for treating seborrheic skin, acne and / or dry skin in a subject, which comprises administering to the skin of a subject in need thereof the above-mentioned skin care composition comprising one of the above-mentioned Staphylococcus strains, a culture supernatant obtained from such a strain, or a combination of these strains or their culture supernatants, or one or more of these strains or their culture supernatants. It is particularly preferred that the subject to be treated is a human.

[0079] The skin to be treated may include the skin of the face and body, such as the skin of the neck, chest, back, arms, hands, legs or thighs. According to a preferred embodiment, the skin treated with the composition of the present invention is the skin of the face. According to another preferred embodiment, the skin treated with the composition of the present invention is the skin of the body.

[0080] The skin care composition can be applied at least once a day, twice a day, or more frequently as needed to the area of the skin in need of treatment, such as the face or body. When applying twice a day, the first and second applications are preferably spaced at least 6 hours, preferably 8 hours apart. Conventionally, the cosmetic composition is applied once in the morning and once at night. The composition of the present invention can be used over a long period of time without harmful side effects. For example, the treatment period can be at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 6 weeks, at least 12 weeks, at least 24 weeks or more. In some embodiments, the treatment is extended for several months, such as 4 months, 6 months, 8 months, 12 months, 18 months or 24 months.

[0081] The skin care composition of the present invention can be provided as an immediately usable composition that enables direct topical administration to the skin. In such a composition, lyophilized or spray-dried live bacteria are present in admixture with other cosmetic or pharmaceutical additives described elsewhere in this specification, such as skin softeners, fillers, etc. When these compositions are applied to the skin, the dried bacteria are reactivated on the skin of the subject to which the product is applied. The growth of the bacteria reactivated from the skin care composition has a positive effect on the microbiota on the skin of the subject.

[0082] These ready-to-use compositions are preferably stable at room temperature for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 8 weeks, at least 10 weeks, at least 12 weeks, at least 14 weeks, at least 16 weeks, at least 18 weeks, at least 20 weeks, at least 22 weeks, at least 24 weeks, at least 26 weeks, at least 28 weeks or at least 30 weeks, or more. When used in the present invention, the composition is considered stable if the decrease in the number of colony-forming units present in the composition after storage is less than a 3 log decrease, preferably less than a 2 log decrease, more preferably less than a 1 log decrease. In other words, the composition is considered stable if the decrease in the number of colony-forming units present in the composition after storage is less than 1000-fold, preferably less than 100-fold, more preferably less than 10-fold, relative to the number of colony-forming units in the composition before storage.

[0083] The skin care composition of the present invention can alternatively be provided as a parts kit in which lyophilized or spray-dried bacteria are spatially separated from other components, such as cosmetic or therapeutic components. For example, the parts kit can be in the form of a package having two spatially separated chambers, with the first chamber containing the lyophilized or spray-dried bacteria and the second chamber containing a cosmetic preparation, such as a cosmetic preparation containing water. Prior to use, the contents of both chambers are mixed with each other, for example by the consumer or patient, to form a homogeneous skin care composition, which is subsequently applied to the skin. The parts kit assembly has the advantage that it can remain in the lyophilized or spray-dried form until use, which is related to the particularly high storage stability of the composition. In the parts kit assembly, the weight ratio of the bacteria in the first chamber to the cosmetic preparation in the second chamber, particularly a cosmetic preparation containing water, is advantageously from 1:10 to 1:100, such as 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100. After mixing the contents of both chambers, the skin care composition preferably contains 1 to 10% by weight of lyophilized or spray-dried bacteria and 99 to 90% by weight of a cosmetic preparation, such as a cosmetic preparation containing water. According to the present invention, the parts kit can be provided, for example, in a Lyo-Ject® double chamber syringe, a V-LK® double chamber carpuel or a dual chamber system. In another preferred embodiment, the lyophilized or spray-dried bacteria in the first chamber may be suspended in a lipid or an oil. This significantly facilitates packaging and filling. In addition, the surrounding lipid or oil protects the bacteria from early rehydration. Preferably, the bacteria are suspended in ethylhexyl palmitate or dicaprylyl carbonate. The weight ratio of the bacteria to the oil or lipid is preferably from 1:1 to 1:2.

[0084] In one embodiment, the skin care composition of the present invention is an aqueous preparation such as a gel. The aqueous preparations contemplated herein include aqueous solutions and aqueous dispersions. In one embodiment, the skin care composition is an oil-in-water emulsion. When the skin care composition contains an oil phase, for example, when using an oil-in-water emulsion, it is preferred that the oil phase contains triglycerides and / or octyldodecanol. In addition, the oil phase may contain one or more oils selected from the group consisting of lecithin, olive oil, sunflower oil, jojoba oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grape seed oil, safflower oil, evening primrose oil, macadamia nut oil, and the like.

[0085] The term "comprising," as used in the context of a method or composition, means that other method steps or composition components may be present in addition to the recited method steps or components. The use of the term "comprising" indicates inclusion rather than limitation. For example, a composition "comprising" components A + B may also contain C as a further component. Similarly, a method "comprising" steps (a) and (b) may also contain (c) as a further method step. In contrast, the term "consisting of," as used in the context of a method or composition, refers to a method or composition that contains no other method steps or composition components not described in the respective composition or method description. For example, a composition "consisting of" components A + B is limited to these two components and contains no other components other than A and B. Similarly, a method "consisting of" steps (a) and (b) is a two-step method and contains no other method steps other than (a) and (b). However, it should be understood that any method or composition described herein as "comprising" a particular method step or component may preferably "consist essentially of" the recited method step or component, or more preferably "consist of" the recited method step or component. Further, unless the context otherwise requires, singular terms shall include the plural, and plural terms shall include the singular.

[0086] Example In the following examples, certain preferred embodiments of the present invention will be described. However, it should be noted that the present invention is not limited to such embodiments.

[0087] Example 1 : Sampling and processing of samples Cotton swab samples were collected from the skin of the forehead, cheeks, back, and forearms of 30 volunteers (14 females, n = 14; 16 males, n = 16) aged 22 - 43 years as previously described (Ahle et al., 2020). Briefly, areas of 25 cm 2 of the skin of the forehead, cheeks, and back, and 50 cm 2 of the skin of the forearm were swabbed with a cotton swab pre - moistened with an aqueous sampling buffer containing disodium phosphate (12.49 g / L, Merck), potassium dihydrogen phosphate (0.63 g / L, Merck), and 1% Triton X - 100 (Sigma). After vigorously shaking the cotton swab in a tube containing 2 mL of the sampling buffer, it was removed. The samples were stored at - 20 °C before DNA extraction. The skin moisture and sebum levels were measured using a Corneometer (Courage + Khazaka electronic) and a Sebumeter (Courage + Khazaka electronic), respectively. None of the volunteers had a history of skin diseases and had not received treatment with topical medications or antibiotics in the past six months. Written informed consent was obtained from all volunteers, and the study was approved by the International Medical & Dental Ethics Commission GmbH (IMDEC) in Freiburg (study number 67885).

[0088] The cotton swab samples were diluted with 0.9% NaCl solution (back, cheek, and forehead skin samples: 1:10 and 1:1000; forehead skin samples: 1:1 and 1:100). Cultivation was carried out by plating on Columbia agar medium supplemented with 5% sheep blood, and the agar plates were incubated at 37 °C for 24 hours. The number of CFUs was determined using an automatic colony counter (IUL). Based on the colony size and color, up to 5 colonies resembling Staphylococcus were randomly selected from each plate and subcultured on the same agar medium to obtain pure cultures. Each of the 572 isolates obtained was assigned to the species level by MALDI-TOF mass spectrometry.

[0089] Before DNA extraction, the skin cotton swab samples were centrifuged (8,000 g, 30 minutes at 4 °C), and the supernatant was discarded. The pellet was lysed using lysostaphin (0.05 mg / mL, Sigma) and lysozyme (9.5 mg / mL, Sigma). DNA was extracted using the DNeasy PowerSoil Kit (QIAGEN) according to the manufacturer's instructions. The DNA concentration was measured using a Qubit fluorometer with the Qubit dsDNA HS Assay (ThermoFisher Scientific).

[0090] Result: A total of 572 bacterial isolates were obtained by selective culture, of which 557 were identified as coagulase-negative Staphylococcus (CoNS) by MALDI-TOF mass spectrometry. At all skin sites, the majority of the isolates were identified as S. epidermidis (n = 374, 67.2%), followed by Staphylococcus hominis (n = 86, 15.4%). At the skin sites of the forehead, cheek and back, strains of S. epidermidis were dominant, followed by Staphylococcus capitis (relative abundances of 74.5% and 11.7% respectively), while at the skin site of the forearm, strains of S. hominis and Staphylococcus haemolyticus were more frequently isolated (relative abundances of 38.7% and 7.3% respectively). The water content (skin moisture content) was highest on the skin of the back and forehead compared to the skin of the cheek and forearm (Figure 1). The latter sites showed the highest sebum content and the number of Staphylococcus per 1 cm 2 showed the number of colony-forming units (CFU), but the skin site of the forearm had particularly low sebum and Staphylococcus counts (Figures 2 and 3).

[0091] Example 2 : Effect of S. epidermidis on the abundance of C. acnes on the skin To identify Staphylococcus isolates with bioactivity, all 557 CoNS isolates were screened for antimicrobial properties against the indicator strain DSM1897. For this purpose, bacterial lawn plates were prepared for the indicator strain. A liquid culture of the C. acnes indicator strain was prepared in CASO broth. In the C. acnes strain culture, the liquid culture was adjusted to OD 600nmIt was adjusted to an optical density of 0.075. 6 mL of the adjusted culture was pipetted onto a rectangular Tryptic Soy Agar (TSA) plate and evenly distributed. For the circular TSA plate, 3 mL of the bacterial suspension was used. After 30 seconds, the excess liquid was removed and the plate was dried for 4 hours. The plates were stored at 4 °C for up to 3 weeks.

[0092] CoNS isolates were cultured with shaking at 37 °C for 20 hours in 1 mL of CASO broth in a 96 Deepwell plate. The 96 Deepwell plate was centrifuged at 2000 rpm for 5 minutes, 500 μL of the supernatant was removed, and the pellet was resuspended in the remaining liquid. The concentrated bacterial culture was transferred to a 96-well U-bottom plate. The bacterial culture was transferred to a rectangular lawn plate using a replicator stamp. After drying for 4 hours, the plates were cultured under various conditions (S. aureus lawn plates: 24, 37 °C; C. acnes lawn plates: 4 - 5 days, 37 °C, in an anaerobic container using an AnaeroGen bag (Thermo Scientific)). The visible inhibition zone around the staphylococcus colonies was regarded as antimicrobial activity. Staphylococcus strains showing antimicrobial properties were verified in triplicate. These strains were further tested against 11 different C. acnes indicator strains from 6 different SLST classes.

[0093] Result: A total of 30 of the Staphylococcus strains tested were observed to exhibit activity against C. acnes strains. These isolates were further screened against 11 different C. acnes strains covering six different SLST classes (A, C, D, H, K, L) including both types associated with acne and healthy skin to identify any lineage-specific biological activity. Of these 30 Staphylococcus isolates, 17 were identified as S. capitis, 6 as S. hominis, 5 as S. epidermidis, and 2 as S. warneri. Strains belonging to different C. acnes phylogenetic clades showed markedly different susceptibilities to the antimicrobial activity of the various Staphylococcus isolates. The two A-class C. acnes strains DSM1897 and 12.1.L1 were the most sensitive to this biological activity and were inhibited by the antimicrobial activity, being inhibited by a total of 29 and 15 Staphylococcus strains, respectively.

[0094] To gain insight into the in vivo relevance of these observations, the relative abundance profiles of C. acnes populations from skin samples with and without antimicrobial-active Staphylococcus strains were compared. Notably, the relative abundance of class A C. acnes was significantly lower at skin sites containing Staphylococcus strains exhibiting antimicrobial activity. This inverse correlation in abundance was most prominent in back skin samples. In samples containing antimicrobial-active Staphylococcus, the relative abundance of class D C. acnes increased significantly, and correspondingly, class A C. acnes decreased (p = 0.004 and p = 0.0013, respectively).

[0095] Example 3 : Preparation of skin care compositions S. capitis strain HAC349 and S. epidermidis strain HAC588 were incorporated into the skin care composition. For this purpose, freeze-dried powders of S. capitis HAC349 and S. epidermidis HAC588 were prepared and mixed with the other components shown below. The components are listed in %(w / w).

[0096]

Table 1

[0097] Example 4 : Preparation of a two-component skin care composition S. epidermidis strain HAC26 and S. warneri strain HAA333 were incorporated into the two-component skin care composition. For this purpose, freeze-dried powders of S. epidermidis HAC26 and S. warneri HAA333 were prepared and mixed with the other components shown below. The components are listed in %(w / w).

[0098]

Table 2

[0099]

Table 3

[0100] The viability of the freeze-dried strains formulated as Formulation 1A and Formulation 1B described in the above table was tested. As shown in Figure 5, it was found that the strains remained viable even after 4 months of storage.

[0101] Next, 25.96% of the bacterial-containing composition 1A or 1B, respectively, was mixed with 74.04% of the carrier composition 2 immediately before product application. The test product was applied to the volar forearms of 12 volunteers at 25 cm 2It was applied once a day for 4 consecutive days to the test site. 1 cm 2 An amount of 2.12 mg of the test product per cm was applied at 1×10 6 CFU / cm 2 It was applied. A total of 53 mg of the test product was applied per 25 cm 2 Cotton swab samples were collected before application (baseline) and 24 hours after the last application (day 5). DNA was extracted from the cotton swab samples, and the staphylococcus composition was analyzed by tuf sequencing (Ahle et al, 2021) as previously described, as well as by strain-specific primers and probes.

[0102] Result : The strain S. epidermidis HAC26 could be specifically detected 5 days after applying the product consisting of formulations 1A and 2 in the above table to the skin. Similarly, the strain S. warneri HAA333 could be specifically detected 5 days after applying the product consisting of formulations 1B and 2 in the above table to the skin.

[0103] Literature Ahle CM, et al. Staphylococcus saccharolyticus: An Overlooked Human Skin Colonizer, Microorganisms 2020, 8. Ahle CM, et al. Comparison of three amplicon sequencing approaches to determine staphylococcal populations on human skin, BMC Microbiol, 2021, 21(1):221. Lomholt HB, Kilian M. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS One 5, e12277 (2010). McDowell A, Nagy I, Magyari M, Barnard E, Patrick S. The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution. PLoS One 8, e70897 (2013). Scholz CF, Jensen A, Lomholt HB, Bruggemann H, Kilian M. A novel high-resolution single locus sequence typing scheme for mixed populations of Propionibacterium acnes in vivo. PLoS One 9, e104199 (2014). Dagnelie MA, et al. Decrease in Diversity of Propionibacterium acnes Phylotypes in Patients with Severe Acne on the Back. Acta Derm Venereol 98, 262-267 (2018). Lomholt HB, Scholz CFP, Bruggemann H, Tettelin H, Kilian M. A comparative study of Cutibacterium (Propionibacterium) acnes clones from acne patients and healthy controls. Anaerobe 47, 57-63 (2017). McDowell A, et al. An expanded multilocus sequence typing scheme for propionibacterium acnes: investigation of ‘pathogenic’, ‘commensal’ and antibiotic resistant strains. PLoS One 7, e41480 (2012). McDowell A, et al. A novel multilocus sequence typing scheme for the opportunistic pathogen Propionibacterium acnes and characterization of type I cell surface-associated antigens. Microbiology (Reading) 157, 1990-2003 (2011). Nakase K, Hayashi N, Akiyama Y, Aoki S, Noguchi N. Antimicrobial susceptibility and phylogenetic analysis of Propionibacterium acnes isolated from acne patients in Japan between 2013 and 2015. J Dermatol 44, 1248-1254 (2017). Nakase K, et al. Characterization of acne patients carrying clindamycin-resistant Cutibacterium acnes: A Japanese multicenter study. J Dermatol 47, 863-869 (2020).

Claims

1. A skincare composition for topical administration to the skin, comprising one or more Staphylococcus strains that exhibit specific antimicrobial activity against pathogenic Cutibacterium acnes strains, or the culture supernatant of such Staphylococcus strains.

2. The aforementioned one or more Staphylococcus strains (a) S. hominis strain HAA254 deposited with DSMZ under accession number DSM 34166, (b) S. hominis strain HAA272 deposited in DSMZ under accession number DSM 34167, (c) S. capitis strain HAB56, deposited with DSMZ under accession number DSM 34177. (d) S. capitis strain HAB177 deposited in DSMZ under accession number DSM 34178, (e) S. capitis strain HAB198 deposited in DSMZ under accession number DSM 34179, (f) S. capitis strain HAB276, deposited in DSMZ under accession number DSM 34197, (g) S. hominis strain HAC286, deposited in DSMZ under accession number DSM 34168, (h) S. capitis strain HAC349, deposited in DSMZ under accession number DSM 34198, (i) S. capitis strain HAC470, deposited in DSMZ under accession number DSM 34199, (j) S. capitis strain HAC507, deposited in DSMZ under accession number DSM 34200, (k) S. epidermidis strain HAC588, deposited in DSMZ under accession number DSM 34158, (l) S. epidermidis strain HAF242, deposited in DSMZ under accession number DSM 34159, (m) S. capitis strain HAF401, deposited with DSMZ under accession number DSM 34153, (n) S. epidermidis strain HAF424 deposited in DSMZ under accession number DSM 34160, (o) S. epidermidis HAC26, deposited in DSMZ with accession number DSM 34117, and (p) S. Warneri HAA333, deposited in DSMZ with accession number DSM 34118. A skincare composition according to claim 1, selected from the group consisting of the following.

3. The skincare composition according to claim 1, wherein the Staphylococcus strain is present in the composition in a freeze-dried or spray-dried form.

4. The aforementioned Staphylococcus strain, (a) 10 of the skin care composition ４ ~10 １１ CFU / ml, preferably 10% of the skincare composition ７ ~10 １０ CFU / ml, and / or (b) at least 0.5% (w / v) of the skincare composition The skincare composition according to claim 1, wherein the above is present in the composition in the amount of .

5. The composition is (a) 10 of the skin care composition ４ ~10 １１ S. hominis strain HAA254, deposited in DSMZ with accession number DSM 34166 in a volume of CFU / ml. (b) 10 of the skincare composition ４ ~10 １１ S. hominis strain HAA272, deposited in DSMZ with accession number DSM 34167 in a volume of CFU / ml, (c) 10 ４ to 10 １１ S. capitis strain HAB56 deposited with DSMZ under accession number DSM 34177 in an amount of 10 (d) 10 of the skin care composition ４ ~10 １１ S. capitis strain HAB177, deposited in DSMZ with accession number DSM 34178 in a volume of CFU / ml. (e) 10 of the skin care composition ４ ~10 １１ S. capitis strain HAB198, deposited in DSMZ with accession number DSM 34179 in a volume of CFU / ml. (f) 10 of the skincare composition ４ ~10 １１ S. capitis strain HAB276, deposited in DSMZ with accession number DSM 34197 in a volume of CFU / ml, (g) 10 of the skincare composition ４ ~10 １１ S. hominis strain HAC286, deposited in DSMZ with accession number DSM 34168 in a volume of CFU / ml. (h) 10 of the skincare composition ４ ~10 １１ S. capitis strain HAC349, deposited in DSMZ with accession number DSM 34198 in a volume of CFU / ml, (i) 10 of the skincare composition ４ ~10 １１ S. capitis strain HAC470, deposited in DSMZ with accession number DSM 34199 at a volume of CFU / ml. (j) 10 of the skincare composition ４ ~10 １１ S. capitis strain HAC507, deposited in DSMZ with accession number DSM 34200 in a volume of CFU / ml. (k) 10 of the skin care composition ４ ~10 １１ S. epidermidis strain HAC588, deposited in DSMZ at a volume of CFU / ml under accession number DSM 34158, (l) 10 of the skincare composition ４ ~10 １１ S. epidermidis strain HAF242, deposited in DSMZ with accession number DSM 34159 in a volume of CFU / ml, (m) 10 of the skincare composition ４ ~10 １１ S. capitis strain HAF401, deposited in DSMZ with accession number DSM 34153 in a quantity of CFU / ml, (n) 10 of the skincare composition ４ ~10 １１ S. epidermidis strain HAF424, deposited in DSMZ with accession number DSM 34160 in a volume of CFU / ml. (o) 10 of the skincare composition ４ ~10 １１ S. epidermidis HAC26 deposited in DSMZ in a quantity of CFU / ml under accession number DSM 34117, and / or (p) S. Warneri HAA333, deposited in DSMZ with accession number DSM 34118. A skincare composition according to claim 1, comprising:

6. The skincare composition according to claim 5, wherein the composition comprises two or more Staphylococcus strains in substantially equal concentrations.

7. The skincare composition according to claim 1, further comprising one or more additives.

8. The skincare composition according to claim 7, wherein one or more of the additives include a emollient, a filler, a thickener, a solubilizer, an antioxidant, a preservative, a pH adjuster, a binder, a buffer, a colorant, a humectant, an exfoliant, a preservative, a plant extract, an essential oil, or a fragrance.

9. The skincare composition according to claim 1, wherein the composition is in the form of a gel, cream, ointment, or lotion.

10. (a) S. hominis strain HAA254 deposited with DSMZ under accession number DSM 34166, (b) S. hominis strain HAA272 deposited in DSMZ under accession number DSM 34167, (c) S. capitis strain HAB56, deposited with DSMZ under accession number DSM 34177. (d) S. capitis strain HAB177 deposited in DSMZ under accession number DSM 34178, (e) S. capitis strain HAB198 deposited in DSMZ under accession number DSM 34179, (f) S. capitis strain HAB276, deposited in DSMZ under accession number DSM 34197, (g) S. hominis strain HAC286, deposited in DSMZ under accession number DSM 34168, (h) S. capitis strain HAC349, deposited in DSMZ under accession number DSM 34198, (i) S. capitis strain HAC470, deposited in DSMZ under accession number DSM 34199, (j) S. capitis strain HAC507, deposited in DSMZ under accession number DSM 34200, (k) S. epidermidis strain HAC588, deposited in DSMZ under accession number DSM 34158, (l) S. epidermidis strain HAF242, deposited in DSMZ under accession number DSM 34159, (m) S. capitis strain HAF401, deposited with DSMZ under accession number DSM 34153, (n) S. epidermidis strain HAF424 deposited in DSMZ under accession number DSM 34160, (o) S. epidermidis HAC26, deposited in DSMZ with accession number DSM 34117, and (p) S. Warneri HAA333, deposited in DSMZ with accession number DSM 34118. A Staphylococcus strain selected from the group consisting of the above, or a culture supernatant obtained from any of the above strains (a) to (p).

11. A skincare composition according to any one of claims 1 to 9, or a bacterial strain or culture supernatant according to claim 10, used in a method for treating acne, oily skin and / or dry skin in a subject.

12. A skin care composition or bacterial strain or culture supernatant used in the method according to claim 11, wherein the composition is administered daily.

13. A skincare composition according to any one of claims 1 to 9, or a bacterial strain or culture supernatant according to claim 10, used in a method for reducing the number of pathogenic C. acnes cells on the skin of a subject.

14. A skin care composition according to any one of claims 1 to 9, or a bacterial strain or culture supernatant according to claim 10, used in a method for treating a skin infection of a subject caused by a pathogenic C. acnes strain.

Images